Skip to content
OpenCapital
Get started
ADC Therapeutics logo

ADC Therapeutics (ADCT) Q1 2026 Earnings

ADCT·Reported May 4, 2026·Before market open

ADC Therapeutics reported Q1 2026 revenue of $20.9M (-9.5% YoY), beat analyst consensus of $20.0M by $864.2K. Diluted EPS came in at $-0.21 (+41.7% YoY), missed the $-0.19 consensus by $0.02.

Revenue
$20.9Mbeat by $864.2K
Consensus: $20.0M
Diluted EPS
$-0.21missed by $0.02
Consensus: $-0.19
SEC

SEC Filings

Earnings release8-K · 0001628280-26-029524
Quarterly report10-Q · 0001628280-26-029819

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about ADC Therapeutics's Q1 2026 earnings report.

ADC Therapeutics (ADCT) reported Q1 2026 earnings on May 4, 2026 before market open.

ADC Therapeutics reported revenue of $20.9M and diluted EPS of $-0.21 for Q1 2026.

Revenue beat the consensus estimate of $20.0M by $864.2K. EPS missed the consensus estimate of $-0.19 by $0.02.

Compared to the same quarter a year prior, revenue declined 9.5% from $23.0M a year earlier and diluted EPS grew 41.7% from $-0.36.

You can read the 8-K earnings release (0001628280-26-029524) and the 10-Q periodic report (0001628280-26-029819) directly on SEC EDGAR. The filing index links above go to sec.gov.